Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Study About the Response to the Administration of a Third Dose of mRNA-1273 Vaccine (COVID-19 Vaccine Moderna) in Renal Transplants With Immunological Failure Initial to Vaccination

Next Previous
Trial Profile

Study About the Response to the Administration of a Third Dose of mRNA-1273 Vaccine (COVID-19 Vaccine Moderna) in Renal Transplants With Immunological Failure Initial to Vaccination

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 27 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Elasomeran (Primary)
  • Indications COVID 2019 infections
  • Focus Therapeutic Use
  • Acronyms VAX-TRES

Most Recent Events

  • 22 Jun 2025 Planned initiation date changed from 1 Aug 2021 to 1 Sep 2021.
  • 23 Feb 2024 Status changed from withdrawn prior to enrolment to discontinued.
  • 17 Feb 2023 Status changed from recruiting to withdrawn prior to enrolment. No candidates for the trial (all patients have received the third dose of the vaccine)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top